Sophia Kamran, MD, discusses potential toxicities limiting the addition of immunotherapy to trimodal therapy for patients with urothelial cancer.
Jonah Feldman
Jonah Feldman is an assistant editor for Targeted Oncology and Peers and Perspectives in Oncology.
Articles by Jonah Feldman
Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.
FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.
The 5-year analysis of the CheckMate 227 study shows long-term survival benefit for nivolumab plus ipilimumab versus chemotherapy in patients with metastatic non–small cell lung cancer.
During an interview with Targeted Oncology, Shifeng S. Mao, MD, discussed what current and upcoming clinical studies have led to improvements in how physicians treat urothelial cancer.
Allegheny Health Network and Illumina, Inc. announced a collaborative effort to assess their in-house comprehensive genomic testing to analyze the role of genetic tests in improving cancer care.
In an interview with Targeted Oncology, Stephen M. Karlovits, MD, discussed key developments that researchers have made in the primary brain tumor treatment landscape in recent years and upcoming trials with potential to improve outcomes for patients.
A new trial will investigate the combination of ZEN-3694 and talazoparib in patients who previous received a TROP2 antibody-drug conjugate.
Darolutamide plus androgen deprivation therapy and docetaxel was not associated with an increase in incidence or severity of adverse events versus androgen deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.
Surface Oncology announced the initiation of new trials of the investigational agent SRF388 in patients with hepatocellular carcinoma and non–small cell lung cancer.
Oncternal Therapeutics announced it would terminate its study of ONCT-216 for patients with Ewing sarcoma and prioritize its phase 3 ZILO-301 study of zilovertamab plus ibrutinib for patients with relapsed/refractory mantle cell lymphoma.
Investigators in the MyPathway basket study found that the ALK inhibitor alectinib had clinical responses to ALK rearrangements in solid tumors but not other ALK alterations.
Based on an interim analysis of a randomized phase 2 trial, use of topical ruxolitinib showed reduced body surface area of chronic graft-versus-host disease.
Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.
Chimeric antigen receptor T-cell therapy showed early efficacy and a tolerable safety profile with or without an mRNA vaccine in a phase 1 clinical trial.
Part 2 of the phase 1/2 trial investigating LUT014, a topical agent for radiation-induced dermatitis in patients with breast cancer, completed its enrollment of 20 patients.
The PROPHETIC trial of a predictive diagnostic analysis platform expanded to a new site at Roswell Park Comprehensive Cancer Center in Buffalo, New York.
The phase 1 ADVANCED-1 trial of the biologic immunopotentiator agent TARA-002 began dosing patients with non-muscular invasive bladder cancer.
The FDA has given the targeted inhibitor alrizomadlin a rare pediatric disease designation for the treatment of neuroblastoma.
Lisocabtagene maraleucel has demonstrated benefit to event-free survival for patients with relapsed/refractory large B-cell lymphoma.
The FDA has released a draft of new recommendations for the manufacture, development, and study design of chimeric antigen receptor T cells.
The KEYLYNK-010 trial of pembrolizumab and olaparib was terminated following negative overall survival results in patients with metastatic castration-resistant prostate cancer.
The AALL1231 trial of bortezomib showed survival benefit for children with T-cell lymphoblastic lymphoma and significantly reduced need for cranial radiotherapy in patients with T-cell acute lymphoblastic leukemia.
A multivariate analysis of response rates of patients with metastatic renal cell carcinoma identified which factors are associated with a partial or complete response to first-line doublet immunotherapy or immunotherapy/tyrosine kinase inhibitor combinations.
The phase 3 NuTide:121 study of acelarin was terminated due to failing to meet a primary end point of overall survival benefit.
A biotherapeutic led to improved efficacy of immunotherapy in a phase 1 study of patients with metastatic renal cell carcinoma.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, and while many trials have failed to change the standard of care and improve outcomes, new opportunities for targeted treatment are growing, according to Brian T. Hill, MD, PhD.
The phase 2 PERICLES trial of atezolizumab with or without radiotherapy in patients with stage IV cancer did not meet its primary end point of 1-year progression-free survival.
Nathan Bahary, MD, discussed with Targeted Oncology how the cholangiocarcinoma treatment paradigm has changed and what is on the horizon for treatment and care of patients.